These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32609290)

  • 1. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
    ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
    Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
    Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.
    Salama S; Giovannoni G; Hawkes CH; Lechner-Scott J; Waubant E; Levy M
    Mult Scler Relat Disord; 2020 Jul; 42():102259. PubMed ID: 32571580
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
    Brownlee W; Bourdette D; Broadley S; Killestein J; Ciccarelli O
    Neurology; 2020 Jun; 94(22):949-952. PubMed ID: 32241953
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19 in MS and NMOSD: A multicentric online national survey in Chile.
    Ciampi E; Uribe-San-Martín R; Soler B; Fernández R; García P; Navarrete-Asenjo C; Tirapegui JM; Torres R; Polanco J; Suárez F; Cuello MJ; Cárcamo C
    Mult Scler Relat Disord; 2020 Oct; 45():102392. PubMed ID: 32683306
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 will change MS care forever - No.
    Preziosa P; Rocca MA; Filippi M
    Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
    Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
    Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.
    Tomczak A; Han MH
    Mult Scler Relat Disord; 2020 Oct; 45():102347. PubMed ID: 32645636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
    Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
    Front Immunol; 2020; 11():1059. PubMed ID: 32477373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The COVID-19 pandemic and the use of MS disease-modifying therapies.
    Giovannoni G; Hawkes C; Lechner-Scott J; Levy M; Waubant E; Gold J
    Mult Scler Relat Disord; 2020 Apr; 39():102073. PubMed ID: 32334820
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic].
    Nakamura M; Nakashima I
    Brain Nerve; 2020 Oct; 72(10):1079-1083. PubMed ID: 33051396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
    Guevara C; Villa E; Rosas CS; Diaz V; Naves R
    Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
    [No Abstract]   [Full Text] [Related]  

  • 15. Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm.
    Valero-López G; Carreón-Guarnizo E; Hernández-Clares R; Iniesta-Martínez F; Jiménez-Veiga J; Moreno-Docon A; Iborra-Bendicho MA; Aznar-Robles E; Hellín-Gil MF; Morales-Ortiz A; Meca-Lallana JE
    Neurologia (Engl Ed); 2020; 35(6):357-362. PubMed ID: 32591152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teledermatology for acne patients: How to reduce face-to-face visits during COVID-19 pandemic.
    Villani A; Annunziata MC; Abategiovanni L; Fabbrocini G
    J Cosmet Dermatol; 2020 Aug; 19(8):1828. PubMed ID: 32490578
    [No Abstract]   [Full Text] [Related]  

  • 17. Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    Gelibter S; Pirro F; Saraceno L; Susani E; Moioli MC; Puoti M; Agostoni EC; Protti A
    J Neuroimmunol; 2023 Oct; 383():578199. PubMed ID: 37717427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Logistic precautions in preparation and administration of allergen immunotherapy during the COVID-19 pandemic in Mexico].
    Larenas-Linnemann D; Del Río-Navarro BE; Luna-Pech J; Navarrete-Rodríguez EM; Pozo-Beltrán CF; Arias-Cruz A; Costa-Domínguez MC; Rodríguez-González M; Blandón-Vijil MV; Estrada-Cardona A; Gereda JE; Ortega-Martell JA; Rodríguez-Pérez N; Rojo-Gutiérrez MI; Espinosa-Rosales FJ; Martínez-Infante EA
    Rev Alerg Mex; 2020; 67(2):199-201. PubMed ID: 32892535
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile.
    Ciampi E; Uribe-San-Martin R; Cárcamo C
    Mult Scler Relat Disord; 2020 Jul; 42():102204. PubMed ID: 32570203
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of MS disease-modifying therapies on responses to vaccinations: A review.
    Ciotti JR; Valtcheva MV; Cross AH
    Mult Scler Relat Disord; 2020 Oct; 45():102439. PubMed ID: 32769063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.